What is Pressure Biosciences Inc?
develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide.
PBIO · Verdict
Moderate reward · high risk
PBIO stands out on volatility and growth, but watch the balance sheet signal.
Based on 88% data coverage
PBIO · Verdict
Above average
Rev +17.5% CAGR · earnings +22.3%
Current ratio 0.02
-161% free-cash-flow margin
-1482% net margin · 0% ROE
Model-based scoring. For information only — not financial advice.
develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company's products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 20.48K.
The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.